As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in:
- Brain tumours (primary or metastatic)
- Lung tumours (especially oat-cell carcinoma)
- Hodgkin’s disease (resistant to conventional combination chemotherapy)
- Malignant melanoma (metastatic)
Lomustine “medac” may also be of value as second-line treatment in Non-Hodgkin’s lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast.